- MDL 12330A hydrochloride
- 1,9-Dideoxyforskolin
- SQ 22536
- NKY 80
- NKH 477
- KH 7
Forskolinadenylate cyclase activator |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 99.07%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Related Biological Data
Related Biological Data
Cell experiment [1, 2]: | |
Cell lines | Human mesenchymal stem cells |
Preparation method | The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0.075-0.2 mM for 4 days or 7 days; or 10 μM |
Applications | Forskolin concentration-dependently decreased human mesenchymal stem cells proliferation after 4 days. Moreover, Forskolin increased alkaline phosphatase (ALP) expression of human mesenchymal stem cells in a dose-dependent manner. Additionally, Forskolin (10 μM) significantly stimulated both vasopressin and oxytocin release from the rat hypothalamo-neurohypophysial (H-NH) system. |
Animal experiment [1]: | |
Animal models | Particles were implanted in subcutaneous pockets of nude male mice model |
Dosage form | 0.10 or 0.15mM Forskolin |
Applications | Treatment with 0.10 mM Forskolin enhanced bone formation by human mesenchymal stromal cells in vivo. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: 1. Doorn, J., Siddappa, R., van Blitterswijk, C. A. and de Boer, J. (2012) Forskolin enhances in vivo bone formation by human mesenchymal stromal cells. Tissue Eng Part A. 18, 558-567 2. Roszczyk, M. and Juszczak, M. (2014) Forskolin-stimulated vasopressin and oxytocin release from the rat hypothalamo-neurohypophysial system in vitro is inhibited by melatonin. Endokrynol Pol. 65, 125-131 |
Forskolin Dilution Calculator
calculate
Forskolin Molarity Calculator
calculate
Cas No. | 66575-29-9 | SDF | Download SDF |
Synonyms | N/A | ||
Chemical Name | [(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate | ||
Canonical SMILES | CC(=O)OC1C(C2C(CCC(C2(C3(C1(OC(CC3=O)(C)C=C)C)O)C)O)(C)C)O | ||
Formula | C22H34O7 | M.Wt | 410.5 |
Solubility | ≥20.525mg/mL in DMSO | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
Forskolin is a cell-permeable activator of adenylyl cyclase [1].
Adenylate cyclase is an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to 3",5"-cyclic AMP (cAMP) and pyrophosphate.
Forskolin is a cell-permeable activator of adenylyl cyclase. In rat cerebral cortical membranes, forskolin reversibly and rapidly activated adenylate cyclase with EC50 value of 5-10 μM. GTP and GDP increased the responses to forskolin. In rat cerebral cortical slices, forskolin rapidly increased cAMP by 35-fold with IC50 values of 25 μM [1]. Forskolin inhibited the inactivation of adenylate cyclases induced by N-ethylmaleimide with Kd values of 7.6 and 6.3 μM for the platelet and brain adenylate cyclases, respectively. Also, forskolin protected adenylate cyclases against thermal inactivation. Forskolin activated the platelet adenylate cyclase with IC50 and Kd values of 3-10 μM and 9-11 μM, respectively [2]. In pig epidermal cells, forskolin activated epidermal adenylate cyclase with Ka value of 2-3×10-5 M and induced cAMP accumulations, which then inhibited mitotic in a dose-dependent way [3].
References:[1]. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci U S A, 1981, 78(6): 3363-3367.[2]. Awad JA, Johnson RA, Jakobs KH, et al. Interactions of forskolin and adenylate cyclase. Effects on substrate kinetics and protection against inactivation by heat and N-ethylmaleimide. J Biol Chem, 1983, 258(5): 2960-2965.[3]. Takeda J, Adachi K, Halprin KM, et al. Forskolin activates adenylate cyclase activity and inhibits mitosis in in vitro in pig epidermis. J Invest Dermatol, 1983, 81(3): 236-240.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
例如:5000个核苷酸残基就是5000×0.15=750纳米
核苷酸(hé gān suān) Nucleotide,一类由嘌呤碱或嘧啶碱、核糖或脱氧核糖以及磷酸三种物质组成的化合物。又称核甙酸。戊糖与有机碱合成核苷,核苷与磷酸合成核苷酸,4种核苷酸组成核酸。核苷酸主要参与构成核酸,许多单核苷酸也具有多种重要的生物学功能,如与能量代谢有关的三磷酸腺苷(ATP)、脱氢辅酶等。
Musmusculus2dayspregnantadultfemaleovaryCDNA,RIKENfull-lengthenrichedlibrary,clone:E330021J16product:inferred:SRY-boxcontaininggene4/sox-4,fullinsertsequence。
product:inferred:SRY-boxcontaininggene4/sox-4,fullinsertsequence是什么意思,这个基因推测产物是sox-4?fullinsertsequence是什么意思?
这个缩写,N是nicotinamideA是腺嘌呤adenineD是二核苷酸dinucleotideP是磷酸基团phosphate那么H是什么的缩写呢?是还原H的意思吗?
上个封面先!
各位战友,你们好!我最近在做载体构建的实验,我打算将一段40bp左右的寡核苷酸连接到载体上,但是做了几次都是阴性结果,求各位大神指教!谢谢
我的操作过程如下:
我是将含有酶切位点的寡核苷酸引物稀释成100uM,各取1ul,加8ul水,95℃5mins,然后自然冷却至室温,然后再将退火后的核苷酸双链稀释了100倍。稀释后的核苷酸双链进行双酶切,酶切体系是:
10xBuffer4ul
Oligo30ul
酶12ul
酶22ul
ddH2O2ul
混匀后37℃水浴40min,在用65℃将酶变性20min
接下来就将寡核苷酸与双酶切回收载体连接(确认已经酶切开)
连接体系:
载体:2ul
oligo:10ul
10xT4buffer:2ul
T4连接酶:2ul
ddH2O:4ul
16℃连接过夜。
转化克隆后,挑取单克隆测序,发现全是没有连上,可能是什么原因呢?能帮忙解答一下吗?
以前听说过设计引物,以引物互为模板进行PCR获得的引物二聚体就是目的片段
有没有人具体操作过呢?应该注意什么问题呢?比如引物设计,体系,PCR程序
我冻干的5‘-核苷酸酶在固体状态挺稳定,但是复溶之后的液体状态分别在4℃和-20℃保存7天后,4℃保存的浓度下降20%以上,-20℃保存的没降。这是什么原因?该怎么解决?
核苷类药按其结构,也可分为3类: ① L-核苷类:,如拉米夫定和替比夫定;为嘧啶类②
无环磷酸盐类,阿德福韦酯和替诺夫韦;为嘌呤类,③ 环戊烷 /
烯类,如恩替卡韦。现在上市的有拉米夫定、替比夫定、阿德福韦和恩替卡韦;将要上市的还有替诺福韦。这一类新的药物还在不断研发,还会有更好的药物问世。
这一类药物有共同的特点。优点是应用方便,每天服一片药就行了;安全性强,很少不良反应,几乎没有禁忌症;最重要的是抑制病毒复制的活性很强,能较快改善病情。共同的缺点是需要长期用药,随意停药可能有反弹的风险;不计划、不规范用药容易发生耐药变异。
1、拉米夫定(贺普丁)有什么特点?
拉米夫定是第一个研发出来的口服抗病毒药,已经上市10年了,治疗了上百万人,救治了无数病人,取得了丰富的经验。
在上述几种口服抗病毒药中,拉米夫定抑制病毒复制的活性居于中等水平,一年平均可降低对数的5次方(即降到治疗前的1/10万)。随着病毒水平的降低,有七成病人血清转氨酶在3个月内降至正常;自觉症状也随之改善;肝组织病变在6个月内会有明显进步。肝硬化病人的恢复要慢一些。
拉米夫定是最安全的核苷类药,价格也较适当,过去、现在和在近期内都是应用最广泛的抗病毒药物,一个月的费用约460圆。
但拉米夫定也是最容易发生耐药变异的,每年以20%的比率递增。过去由于“一花独秀”,也有过一些误导,使我国有众多耐药变异的乙肝病毒感染者,因对其他核苷类药可能会发生交叉耐药,造成治疗困难。今后如能吸取教训,使用得当,仍不失为一个好药。
2、阿德福韦有什么特点?
阿德福韦抑制病毒复制的作用稍弱,1年降低4次方,故控制病情较缓慢,1年只有半数的病人血清转氨酶正常。但阿德福韦发生耐药变异较少,只要血清病毒长期维持在很低的复制水平,就有可能较长时间稳定控制病情。
阿德福韦是我国拥有自主知识产权的新药,目前国内有多家企业生产。在多种核苷类药物中,价格是最低的(一个月的费用约430圆),而且药品价格还在不断下调中。既能解决患者问题,又不至于增添患者太多经济负担。
但要注意的是:老年病人和肝移植病人可能有潜在的肾损害,用药中要多做检查。
3、恩替卡韦有什么特点?
恩替卡韦,在已经上市和尚未上市的几种药物中,抑制病毒复制的活性最强,一年平均可降低对数的7次方,几乎是拉米夫定的100倍,对极大多数病毒水平很高的病人也能在1年左右降至不能检出。早期作用更明显,头2周就能降低2次方,对救治重症病人特别有利。在肝移植病人可用于抑制病毒复现,可长期应用预防再感染导致的移植肝排斥。
恩替卡韦在没有用过核苷类药的初治病人,耐药变异的发生率很低,对已经拉米夫定耐药的病人疗效会明显降低。最大的问题是价格最贵,一个月的费用达1100圆。
4、替比夫定有什么特点?
替比夫定是拉米夫定的同类药,而抑制病毒作用约有拉米夫定的10倍,一年平均可降低血清病毒水平6次方,约60%的病人不能检出病毒。不过这些数据多来源国外,从临床疗效来看,控制病情、HBV-DNA阴转率、变异率稍优于拉米夫定,但从统计学上来分析,没有实际意义的差别。替比夫定一个月的费用约700圆,尚没有纳入国家医保。拉米夫定效果不佳时,可以考虑换用替比夫定,但一年后的耐药率也不低于10%。
怎样正确应用这一类药物?
因为服用这类药物很方便、很安全,有些病人像用止痛片或胃病药一样,随意停停用用,血清转氨酶升高了就用,正常了就停。这样不规范的用药很少有不出问题的,过去曾经有过不少教训。必须在医生指导下,按规定的剂量服药,要定期检查,发现问题要及时处理。
暂无品牌问答